Ensifentrine Suppliers & Bulk Manufacturers
Available Forms: Inhalation solution
Available Strengths: 3 mg per 2.5 mL
Reference Brands: Ohtuvayre (USA)
Category: Respiratory Disorder
Ensifentrine is available in Inhalation solution and strengths such as 3 mg per 2.5 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ensifentrine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Ensifentrine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Ensifentrine is an inhaled medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is marketed under the brand name Ohtuvayre and represents a novel therapeutic approach by combining dual inhibition of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) in a single molecule. This dual mechanism allows ensifentrine to deliver both bronchodilator and anti-inflammatory effects, addressing key pathological features of COPD.
As a PDE3 inhibitor, ensifentrine helps relax airway smooth muscle, leading to bronchodilation and improved airflow. At the same time, its PDE4 inhibitory activity reduces airway inflammation, which contributes to symptom control and disease management. Ensifentrine is administered by inhalation, allowing targeted delivery directly to the lungs and minimizing systemic exposure.
Ensifentrine is indicated for long-term COPD management and is used to improve lung function and reduce respiratory symptoms. Its inhaled formulation makes it suitable for patients who require consistent, localized therapy. By combining bronchodilation and anti-inflammatory action in one treatment, ensifentrine offers a differentiated and effective option for personalized respiratory care in adult COPD patients.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Ensifentrine is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It helps improve lung function and reduce respiratory symptoms associated with COPD.
Ensifentrine is a small-molecule, dual phosphodiesterase (PDE) inhibitor that selectively inhibits PDE3 and PDE4 enzymes involved in airway inflammation and bronchoconstriction.
The trade name of ensifentrine is Ohtuvayre.
Ensifentrine is developed and marketed by Verona Pharma.
The generic name is ensifentrine.
The brand name is Ohtuvayre.
Ensifentrine is manufactured in GMP-compliant pharmaceutical facilities for commercial supply in the United States.
Related Products
Mepolizumab
Strength:
100 mg/1 mL
Form: injection (prefilled syringe)
Reference Brands: Nucala (USA/EU)
View Details
Levalbuterol
Strength:
0.31 mg, 0.63 mg, 1.25 mg
Form: Inhalation solution
Reference Brands: Xopenex (USA/EU)
View Details
Umeclidinium Bromide
Strength:
62.5 mcg
Form: dry-powder inhaler
Reference Brands: Incruse Ellipta (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
